Commercial RisksKey risks include commercial success is not assured since dermatology remains a highly competitive segment, and product concentration risk since Zoryve is the company's only commercial asset.
Generic CompetitionOngoing litigation has weighed on Arcutis shares, affecting the company's trading in-line with Zoryve's commercial performance.
Sales EstimatesQuarter one seasonality is impacting sales estimates, contributing to decreased quarterly sales projections.